seekingalpha.com /1 month ago

Alcon wins approval of OTC Brytly eye drops

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreeme...

Read source
medcitynews.com /4 weeks ago

Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition

Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a...

Read source
fortworthbusiness.com /3 weeks ago

The World’s Next Breakthrough in Eye Care Isn’t Just Innovation. It’s Capacity.

Few things are more fundamental to human potential than the ability to see. Sight helps us connect with others, navigate the world and live independently. Yet, a gap between what i...

Read source
seekingalpha.com /1 week ago

Alcon Q3 2026 Earnings Preview

Read source
biopharmadive.com /5 days ago

J&J bets $2.2B on Ollin’s vision loss drug

The deal hands J&J a treatment that could complement its existing eye care franchise, but would vie for share of a crowded and competitive market.

Read source
medcitynews.com /5 days ago

J&J’s $2.2B Ollin Buyout Brings Late-Stage Eye Drug; Blackstone Deal Adds Trial Funding

Johnson & Johnson’s Ollin Biosciences acquisition comes with a Phase 3-ready bispecific antibody. The companies say this eye drug offers advantages over Vabysmo, a Roche drug a...

Read source
biopharmadive.com /1 month ago

Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal p...

Read source
moneytalksnews.com /1 month ago

Over Half a Million Eye Drops Recalled. See Affected Products

The FDA says this Class II recall could cause temporary or medically reversible harm; users should match product details against the agency's enforcement report.

Read source
newswire.com /1 month ago

Surmodics Launches IOL Cartridge Coating Automation Center in Horsham

New center combines advanced hydrophilic coating technology, IOL cartridge application expertise and automated processing to support scalable ophthalmic device manufacturing

Read source
ksn.com /1 month ago

Almost 750,000 eye drop products, many sold at Walgreens, recalled over 'sterility' concerns

Hundreds of thousands of eye drop products are being recalled under the U.S. Food and Drug Administration's second-highest risk category, according to a recent update.

Read source
drugs.com /1 month ago

Experimental Cataract Lens Can Treat Glaucoma Through Time-Release Drugs

TUESDAY, Oct. 13, 2026 — An experimental cataract lens also can help treat a person’s glaucoma, new clinical trial results show. The artificial lenses carry small pads of a widely...

Read source
investing.com /1 month ago

SpyGlass Pharma reports 4-year glaucoma implant trial results

Read source
aoa.org /1 month ago

Federal judge certifies class action lawsuit against Hubble Contacts

Lawsuit alleges Hubble deceived customers into purchasing contact lenses their eye doctors never prescribed.

Read source
biopharmadive.com /1 month ago

Merck reveals study success, and possible safety worries, for eye drug hopeful

A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate...

Read source
ksnt.com /1 month ago

Over 4.8 million eye drop products recalled nationwide: FDA

TOPEKA (KSNT) – Federal officials report that a company is recalling over 4.8 million eye drop products nationwide due to concerns regarding their sterility. Officials with the Foo...

Read source
labiotech.eu /1 month ago

Shifting the standard: myopia companies to look out for 

Medicines are under review in the clinic to treat myopia. Here are five myopia companies in sight of approval for their therapies.  The post Shifting the standard: myopia companies...

Read source
fool.com /2 weeks ago

Bausch + Lomb: 3 Key Takeaways for Long-Term Investors

Premium product adoption is lifting margins faster than revenue growth, a sign of pricing power in a competitive market.

Read source
aoa.org /1 month ago

AOA's 31 in 31 campaign fights to keep contact lens wearers safe

Take action today to protect patients from illegal and unsafe contact lens sales. The AOA’s 31 in 31 campaign raises awareness for contact lens safety.

Read source
pharmexec.com /1 month ago

<![CDATA[Roundup: CSL & Alentis Enter Global Partnership, Jiangsu Nhwa Enters Global Licensing Deal with Somniver...

Read source
pharmexec.com /1 month ago

<![CDATA[Bausch + Lomb Appoints Thomas Appio as Interim CEO ]]>

Read source
seekingalpha.com /1 month ago

Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow

Read source
opticaljournal.com /1 month ago

VisionLab Brings IOT’s Light-Form Technology To Spanish Consumers

IOT, a Spanish technology company specializing in advanced optical innovation, has developed Light-Form Technology™, a new manufacturing technology that produces ophthalmic lenses...

Read source
seekingalpha.com /1 month ago

Glaukos: Steep Premium For New Therapies And Growth

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.